Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07508995 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07508995: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07508995 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07508995, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.
Interventions
- DRUG BGB-16673
- DRUG BGB-11417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2033-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07508995
The ClinicalTrials.gov registry entry for NCT07508995 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BGB-16673 is the first listed.
NCT07508995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07508995 about?
NCT07508995 is a clinical study titled "A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)". This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.
What is the current status of trial NCT07508995?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-09-01. Estimated completion is 2033-07-01.
What interventions are being tested in trial NCT07508995?
The interventions under investigation include: BGB-16673 (DRUG), BGB-11417 (DRUG).
Who is sponsoring clinical trial NCT07508995?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.